NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









eTheRNA

eTheRNA

Private
NielHealthcare & Life Scienceshttps://www.etherna.be/

Last Round

Series B

Extension

Aug 23, 2022

Total Funding Raised

$103.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

eTheRNA is a biotechnology company that provides mRNA and lipid nanoparticle (LNP) technology platforms for the development and manufacturing of RNA-based therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

mRNA technologylipid nanoparticleLNPdrug delivery platformRNA therapeuticsbiotech platformmRNA vaccinescontract researchGMP manufacturingdrug discoverybiotech partnerRNA medicinedelivery techbiotech CDMO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

eTheRNA Comparables

Compare eTheRNA with similar companies based on industry and business-model similarity.

eTheRNA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Acuitas Therapeutics
86%
Genevant Sciences
84%
Pantherna Therapeutics
83%

eTheRNA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionAug 23, 2022
Series BJun 16, 2020
Series AMar 17, 2016

Key People

Founding team and executive leadership

Bernard Sagaert

Chief Executive Officer

Executive Team

eTheRNA Investors

Notable investors and investment history

eTheRNA investors
InvestorRounds
Yijing CapitalSeries B
Omega FundsSeries B Extension, Series A, Series B
EQT Life SciencesSeries B Extension, Series B, Series A
Fund+Series B Extension, Series A, Series B
Novalis LifeSciencesSeries B Extension, Series B
PMVSeries B Extension, Series B, Series A
Yijing CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 16, 2026

    Monthly visitors grew 48% MoM, reaching 7.8K.

  • Mar 17, 2016

    $27M round led by EQT Life Sciences and PMV.

eTheRNA Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

eTheRNA Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about eTheRNA's valuation, stock price, and market status.

Firmographic Details

HeadquartersNiel
Employee Range89
Year Founded2013
Last FundingAug 23, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.